Abbott Laboratories (ABT)vsLivaNova PLC (LIVN)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
LIVN
LivaNova PLC
$63.30
+1.44%
HEALTHCARE · Cap: $3.40B
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 3094% more annual revenue ($44.33B vs $1.39B). ABT leads profitability with a 14.7% profit margin vs -17.5%. LIVN appears more attractively valued with a PEG of 0.73. ABT earns a higher WallStSmart Score of 51/100 (C-).
ABT
Buy51
out of 100
Grade: C-
LIVN
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Intrinsic value data unavailable for LIVN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
Weak financial health signals
ROE of -19.2% — below average capital efficiency
Earnings declined 45.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : LIVN
The strongest argument for LIVN centers on PEG Ratio, Price/Book. Revenue growth of 12.1% demonstrates continued momentum. PEG of 0.73 suggests the stock is reasonably priced for its growth.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : LIVN
The primary concerns for LIVN are Piotroski F-Score, Return on Equity, EPS Growth.
Key Dynamics to Monitor
ABT profiles as a value stock while LIVN is a turnaround play — different risk/reward profiles.
LIVN carries more volatility with a beta of 0.95 — expect wider price swings.
LIVN is growing revenue faster at 12.1% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (51/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →LivaNova PLC
HEALTHCARE · MEDICAL DEVICES · USA
LivaNova PLC, a medical device company, designs, develops, manufactures and sells therapeutic solutions globally. The company is headquartered in London, the United Kingdom.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?